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Factor XI1 (Hageman factor) is an important element in several 
plasma protease cascades such as the blood coagulation system, 
the kinin system and fibrinolysis (1). Homozygous factor XI1 
deficiency with no enzymatic activity is thought to result in a 
slightly increased risk of venous thromboembolism, but 
placental thrombosis, myocardial infarction and other throm- 
botic complications have been reported in some patients (2,3). 
The factor XI1 protein has the typical features of a member 
of the serine protease family with the active site residues 
encoded by the terminal exons 10-14 (4). To date only a few 
sequence alterations responsible for factor XI1 deficiency were 
found in these exons (5-8). In some patients an additional 
TaqI site in the second intron of the gene was detected. This 
TaqI site was not detected in control groups with normal factor 
XI1 activities (9). We report here a novel mutation termed 
11396 (G+A), a G to A transition at nucleotide position 
1 1396 of the gene. ~ l o o d  samples from 12 patients whose low 
factor XI1 activity was detected by chance during presurgery 
Table 1. Genotypes and factor XI1 parameters for factor XI1 deficient patients 
Patient 11396 (G+A) FX1I:C F XII: Ag PTT (s) 
*denotes unrelated patients from our group of 12 independent cases; 8 denotes 
members of the family described in the pedigree (Fig. 2). Wild type sequence 
(+), mutant sequence (-), FXI1:C = factor XI1 activity, F X1I:AG = factor 
XI1 antigen level, PTT = partial thromboplastin time, n.d. = not determined. 
Table 2. Primer sequences for analysis of exons 13 and 14 as depicted in 
Figure 1 
screening were collected. Genomic DNA was prepared and 
analysed by PCR and direct sequencing for mutations .as 
described (10). RNA preparation and cDNA synthesis with 
subsequent PCR was performed according to Schloesser et al. 
(11). Total RNA from peripheral blood lymphocytes was 
reverse transcribed by exon 14 specific primer and amplified 
in two stages with primers located in exons 11, 12 and 14 
(Tables 1 and 2). For both genomic and cDNA templates PCR 
conditions included pairs of primers (10 pmol) in a total 
Factor XIi prlmary transcript 11 3960->A 
spliclng products 
Wild type cDNA -- 
10 11 12 13 14 
Mutant cDNA  
10 11 12 13 14 
+ + 4 
JM32 EXl2F JM35 
+ C 
EXl3F EX14R2 
Figure 1. Factor XI1 primary transcripts and splicing products as derived 
from the analysis of transcripts. The hatched bar symbolises the truncated 
exon 14 sequences and the aberrant reading frame. 
Figure 2. Family pedigree for patients 97-104. The mutant allele was detected 
in the patients with half filled squares and circles, respectively. Factor XI1 
parameters are listed in Table 1. 
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